Cerebral Palsy
Cerebral Palsy
Cerebral Palsy
Author Manuscript
Clin Obstet Gynecol. Author manuscript; available in PMC 2011 March 9.
Abstract
Cerebral palsy is the most prevalent cause of persisting motor function impairment. In a majority
of cases, the predominant motor abnormality is spasticity; other forms of cerebral palsy include
dyskinetic (dystonia or choreoathetosis) and ataxic cerebral palsy. The care of individuals with
cerebral palsy should include the provision of a primary care medical home for care coordination
and suppor and diagnostic evaluations. Current strategies to decrease the risk of cerebral palsy
include interventions to prolong pregnancy (e.g., 17-progesterone), limiting the number of
multiple gestations related to assisted reproductive technology, antenatal steroids for mothers
expected to deliver prematurely, caffeine for extremely low birth weight neonates, and induced
hypothermia for a subgroup of neonates diagnosed with hypoxic-ischemic encephalopathy.
Keywords
cerebral palsy; function impairment; neuroimaging classification; postnatal prevention
Introduction
Among the variety of disorders that severely impair motor function in young children,
cerebral palsy is the most prevalent. In birth cohorts from developed countries, the
prevalence is 1-2/1000 live births(1). The prevalence rises dramatically with decreasing
gestational age at birth such that among extremely low gestational age newborns (i.e.,
gestational age < 28 weeks), the prevalence is about 100 per 1000 of surviving infant, a 100fold higher risk than infants born at term. As a function of all live births, the prevalence has
been remarkably stable for decades, but this has not been the case among very low birth
weight and very preterm infants, among whom prevalence increased after the introduction of
neonatal intensive care and has begun to decrease in the past decade(1).
In addition to motor manifestations, children with cerebral palsy frequently exhibit cognitive
and sensory impairments, epilepsy, and nutritional deficiencies. Except in the mildest cases,
cerebral palsy has a substantial impact on families well being and societal health care costs.
As a result of both laboratory-based and clinical research over the past several decades, a
few perinatal interventions have been identified which probably are effective for lowering
the risk of cerebral palsy. Successes from clinical research on cerebral palsy has been
enhanced by efforts to increase the reliability (and thereby validity) of the diagnosis and
classification of this disorder. These efforts have improved the efficiency of observational
Address for correspondence: Michael OShea, Department of Pediatrics, Wake Forest University School of Medicine, Medical Center
Blvd, Winston-Salem, NC 27157, Phone: (336)-716-2529, FAX: (336)-716-2525, e-mail address: [email protected].
Sources of support: none to report
OShea
Page 2
In this manuscript I will begin by reviewing research on the diagnosis and classification of
cerebral palsy, including efforts to standardize diagnostic criteria, quantify severity in terms
of motor impairment and impact on quality of life, and classify children with regard to
location and type of neurological abnormality, associated non-motor impairments, and
neuroimaging findings. I will then discuss the care of individuals particularly, children, with
cerebral palsy, with a primary focus on evidence from randomized trials. In concluding I
will discuss preventive interventions that appear likely to have an impact on the risk of
cerebral palsy or that are currently under study in clinical trials. While some of these
interventions are not applicable to obstetric care, it is likely that all will be of interest to
obstetricians.
The diagnosis of cerebral palsy is based on a clinical assessment, and not on laboratory
testing or neuroimaging. A recent international working group offered the following
definition for cerebral palsy: Cerebral palsy is a group of permanent disorders of the
development of movement and posture, causing activity limitation, that are attributed to
non-progressive disturbances that occurred in the developing fetal or infant brain.(2) This
definition allows for heterogeneity of clinical manifestations (a group of ... disorders) and
emphasizes that impaired movement and posture due to a disturbance in the brain is the
invariant clinical manifestation. While the underlying abnormality of the brain is presumed
to be permanent and non-progressive, there is overwhelming evidence that clinical
manifestations and severity of functional impairment often change over time. Thus from a
patients perspective, the term permanent may connate an unduly pessimistic prognosis. In
contrast to earlier definitions of cerebral palsy, that proposed by the aforementioned
international working group included an explicit criterion for the lower limit of abnormality
that must be exceeded in order to diagnose CP, i.e., activity limitation.
On the other hand, this working group did not offer a readily operational approach to the
ascertainment of activity limitation. The approach that appears to be most widely used is
based on a standardized measure of motor function, the Gross Motor Function Classification
System (GMFCS)(3), which will be discussed below in greater detail. The GMFCS has been
included in several recent randomized clinical trials as part of the definition of severity, and
in these trials children with mild cerebral palsy without functional impairment were not
considered to have the outcome of interest. The Western Australian Cerebral Palsy Register
grades severity using the GMFCS, which allows for researchers to include or exclude cases
without functional impairment. In an international study involving prematurely born
children with cerebral palsy, disabling, as opposed to non-disabling cerebral palsy was
ascertained with greater reliability, suggesting that the exclusion of cases without functional
impairment may improve the validity of observational epidemiologic studies as well as
randomized trials in which cerebral palsy is an outcome. Conversely, clinicians should
regard with caution those studies of cerebral palsy in which information is lacking about the
severity of cerebral palsy, as assessed with a reliable measure.
In clinical practice, the diagnosis of cerebral palsy is typically based on observations or
parent reports of attained motor milestones, such as sitting, pulling to stand, and walking,
and evaluation of posture, deep tendon reflexes, and muscle tone. Particularly among infants
born prematurely, neurological abnormalities, observed in the early months of life, may not
be associated with motor impairment and may resolve during the first one or two years of
life. One such abnormality, transient dystonia, was described in early studies of premature
OShea
Page 3
infants and refers to abnormal neurological signs (e.g., hyperextension of the trunk) that are
no longer present after one year of age. Because the diagnosis of cerebral palsy depends in
part on neurological findings that are subject to inter-examiner variation, with regard to both
the method used to elicit the neurological finding as well as the interpretation of the finding,
and because neurological abnormalities may be transient, many clinicians avoid basing the
diagnosis on a single aspect of the parents report or the clinicians examination and
typically will make a definitive diagnosis only after repeated examination(s).
Because cerebral palsy occurs in only 1-2 / 1000 live births, prospective ascertainment of
cases has been limited primarily to cohorts of high risk infants, such as low birth weight
babies, very preterm infants, and infants enrolled in clinical trials. For population-based
studies, registries of children with cerebral palsy have been used, such as those established
in Sweden, Western Australia, Metropolitan Atlanta, and Europe. Children listed in these
registries are identified from records of human services providers and in some studies the
diagnosis is confirmed by examination of medical records or of the child. These population
studies have been particularly informative about trends in prevalence over time.
In many recent studies of high risk infants(4-6), painstaking efforts were directed at
standardizing the definition of cerebral palsy used for prospective identification. With some
minor differences between studies, each of these studies base the definition on a
combination of delayed motor development (either observed or parent-reported), deep
tendon reflexes, posture, and muscle tone (see Figure 1). For more details the reader is
directed to reference(7).
For both clinical as well as research purposes, cerebral palsy has often been classified
according to the nature of the movement disorder (spasticity, ataxia, dystonia, and athetosis)
and the anatomic, or topographic distribution of the motor abnormalities. The predominant
abnormality among children born prematurely is spasticity, referring to a velocity dependent
increase in muscle tone. Spasticity can be assessed clinically as the joint angle at which an
increase muscle tone (resistance to stretch) is encountered. In a much smaller proportion of
cases, referred to as having dyskinetic cerebral palsy, the predominant abnormality is either
dystonia or choreo-athetosis. Dystonia refers to hypertonia and reduced activity;
choreoathetosis, to irregular, spasmodic, involuntary movements of the limbs or facial
muscles. With ataxic cerebral palsy there is a loss of orderly muscular coordination, so that
movements are performed with abnormal force, rhythm, and accuracy.
A traditional classification of children with spastic cerebral palsy includes spastic diplegia
(bilateral spasticity with leg involvement greater than arm), spastic hemiplegia (unilateral
spasticity), or quadriplegia (bilateral spasticity with arm involvement equal to or greater than
leg). In a large population-based study of very low birth weight children with cerebral palsy,
25% of children with spastic CP had hemiplegia, 37.5% had quadriplegia, and 37.5% had
diplegia. Children with hemiplegia almost always develop independent ambulation, whereas
a majority of those with quadriplegia do not. There is some evidence that the profile of risk
factors differs for each of these topgraphic types of cerebral palsy. It should be noted,
however, that the inter-rater reliability of examiners topographic classification is not high;
thus the Surveillance for Cerebral Palsy in Europe (SCPE), a multi-center research
collaboration, has proposed an alternative classification that includes unilateral spastic
cerebral palsy, bilateral spastic cerebral palsy, dystonic cerebral palsy, choreo-athetoid
cerebral palsy, and ataxia (see Figure 2). Currently no method of topographic classification
has been broadly agreed upon.
More agreement has been achieved on classification of cerebral palsy in terms of the
functional severity. More than a decade ago, Palisano and his colleagues developed the
OShea
Page 4
GMFCS, which defines five levels of gross motor function, which have been shown to
correspond to five distinct trajectories of motor development. For example, among
children younger than 2 years, those at level II can maintain floor sitting but may need to
use their hands for support to maintain balance, whereas those at level IV have head control
but trunk support is required for floor sitting. The GMFCS correlates strongly with the
World Health Organization International Classification of Impairments, Disabilities and
Handicap code, but is considerably less time-consuming and can be derived from medical
records. The inter-rater reliability of the GMFCS is high, as is the stability over time. The
GMFCS level of children, as reported by parents, agrees well with that assigned by a
physician; and the level self-reported by adults agrees well with that assigned by a physical
therapist..
Other assessments have been developed for fine motor function, including the ABILHANDKids, the Bimanual Fine Motor Function (BFMF) Classification, and the Manual Ability
Classification System. These assessments have not been studied as extensively as the
GMFCS, but in one study the BFMF correlated strongly with the GMFCS, and in another, a
high level of agreement about the MACS was found between pairs of therapists. Thus a
comprehensive description of an individual with cerebral palsy would include both the
GMFCS as well as a measure of upper extremity (fine motor) function.
Quality of life has been defined as an individuals perception of their position in life in the
context of the culture and value systems in which they live, and in relation to their goals,
expectations, standards and concerns. Using validated instruments which allow children to
self-report on their quality of life, researchers have found that most children with cerebral
palsy report similar quality of life to children not affected with this disorder and that quality
of life is not worse with greater levels of functional impairment(9). In contrast, health
related quality of life, which measures life satisfaction in areas such as self-care, mobility,
and communication is influenced by the severity of impairment.
Neuroimaging classification
Until recently, neuroimaging studies of preterm infants with cerebral palsy were based
largely on neonatal cranial ultrasound. The most widely used classification system, derived
from computed tomography but applied readily to ultrasound findings, was described by
Papile et al. In this approach to classification, grade 1 refers to hemorrhage limited to the
subependymal germinal matrix region, grade 2 refers to hemorrhage in the cerebral
ventricule(s), grade 3 refers to hemorrhage in the ventricle(s) with ventricular enlargement,
and grade 4 refers to hemorrhage in the periventricular cerebrum. More recent approaches to
classification, justified by extensive research, emphasize echolucency in the periventricular
cerebrum and moderate-to-severe ventricular enlargement as most predictive of subsequent
cerebral palsy(10). Very low birth weight infants with either of these abnormalities have a
greater than 50% risk of developing cerebral palsy. For more details see reference (11)
OShea
Page 5
Most children who are born at term and subsequently develop cerebral palsy do not undergo
neuroimaging studies as neonates, but rather, after the diagnosis is suspected. Magnetic
resonance imaging (MRI) is recommended for children with neurological findings
suggestive of cerebral palsy in order to determine if a brain abnormality is present. In a
study of 273 children with cerebral palsy who were born after 35 weeks gestation and
underwent neuroimaging, one third of infants who underwent neuroimaging had normal
studies(12). The most frequent observed abnormality was focal infarction, which was
observed in 22% of the children and 45% of those with hemiplegia. The next most common
finding was brain malformation, including schizencephaly, hydrocephalus, polymigrogyria,
lissenencephaly, agenesis of the cropus callosum, holoprosencephaly, septooptic dysplasia,
and cerebellar anomalies. In 12% of children neuroimaging revealed periventricular
leukomalacia, a finding often is associated with prematurity. Of note is that only 5% of
children had neuroimaging findings considered specific to hypoxia-ischemia(12).
Initial assessments (see Figure 3) for children diagnosed with cerebral palsy include
neuroimaging if the etiology has not been established and metabolic and genetic studies if
clinical history and findings on neuroimaging do not determine a specific etiology or if there
are aspects of the history or physical examination that suggestive of a metabolic or genetic
etiology (including a brain malformation). In addition, testing for prothrombotic
abnormalities of coagulation should be considered in individuals with hemiplegia. All
children with cerebral palsy should be screened for mental retardation, ophthalmologic and
hearing impairment, and speech and language disorders, and nutrition and growth should be
monitored(13).
The American Academy of Pediatrics has emphasized the importance of a primary care
medical home for children with chronic illnesses, including cerebral palsy(8). The roles of
the medical home include care coordination to minimize redundant services and assure
comprehensive services, monitoring of response to treatments and impact of the childs
illness on the family, interpreting findings to the family, orchestrating comanagment with
specialists and specialty teams, and advocating for the patient with payers and providers
such as the public schools(8). (Beginning in 1975, a series of United States public laws has
specified that all handicapped children have available to them a free appropriate education
designed to meet their unique needs. The most recent of these is Public Law 108-446, the
Individuals with Disabilities Education Improvement Act of 2004.)
As discussed above, a large majority of children with cerebral palsy have spasticity. Active
management of spasticity is needed to prevent painful contractures and deformities and
promote optimal function. This management generally is provided by multidisciplinary
teams that include physical therapists, orthopedic surgeons, and physiatrists. Physical
therapy, which is uniformly utilized for cerebral palsy has not been subjected to randomized
trials, but is widely accepted as a component of standard management. Table 1 describes the
results of systematic reviews for five therapies used in the management of spasticity in
patients with cerebral palsy. Those provided by the Cochrane Collaboration can be assessed
at http://www.mrw.interscience.wiley.com/cochrane. For each of these therapies systematic
reviews have provided evidence of benefit. Botulinum toxin type A for management of
spasticity and casting for management of equinus deformity of the foot are probably the
most widely available and used. Dorsal rhizotomy is a more invasive approach to the
management of spastic diplegia and is reserved for the more difficult cases.
Other therapies to improve function in cerebral palsy are listed in Table 2. Therapies specific
for hemiplegia, such as constraint-induced movement therapy (CIMT) and hand-arm
OShea
Page 6
bimanual intensive therapy (HABIT), have been studied in a relatively small number of
individuals. With CIMT, the non-involved upper extremity is restrained and the involved
extremity is engaged in targeted practice. With HABIT, structured tasks requiring bimanual
function are practiced in the context of play and functional activities. While more study is
warranted, these appear to hold promise of benefit. More research on the effects of
hyperbaric oxygen therapy is required, as there is considerable uncertainty about its
efficiency and adverse effects, and this treatment costs approximately $400 per 90-minute
session.
Prognosis
As discussed above, prognosis for independent ambulation depends in large part on the type
of motor impairment. Ambulation status, intelligence quotient, quality of speech, and hand
function together are predictive of employment status. For example, in a study of adults with
cerebral palsy, intelligence quotient 80, and understandable speech, who were ambulatory
and independent of the need for significant assistance, 90% were employed in a
competitive job (i.e., one which could be filled by a similarly qualified person without a
disability).
Mortality also is strongly associated with both the level of functional impairment as well as
associated non-motor impairments. In one study of over 2014 individuals with cerebral
palsy, the strongest predictor of mortality was intellectual disability. For example, among
those with profound intellectual disability (i.e., IQ < 20), only one half survived into
adulthood; whereas among those with IQ > 35, 92% survived to adulthood. More generally,
mortality risk increases incrementally with increasing number of impairments, including
intellectual, limb function, hearing, and vision. In a recent population-based study, the
shortest life expectancy was observed among those individuals who were unable to lift their
head in prone, who had a life expectancy of 20 years.
OShea
Page 7
Nonetheless, because approximately one-half of all new cases of cerebral palsy arise from
the group of neonates born prematurely, it is possible that interventions which either prolong
gestation or decrease the risk of preterm delivery will also decrease the risk of cerebral
palsy. Specific approaches to reduce the rate of preterm birth, that are supported by a high
level of evidence, include limiting the number of embryos transferred with in vitro
fertilization, smoking cessation during pregnancy, screening for and treatment of
asymptomatic bacteriuria during pregnancy, antiplatelet drugs to prevent preeclampsia, 17progesterone caproate, and cervical cerclage for women with previous preterm birth and
short cervix (i.e., < 2.5 centimeters)(20). In addition, interventions which have been shown
to prolong pregnancy include calcium channel blockers and an oxytocin antagonist
(atosiban) for women with preterm labor and erythromycin for women with premature
rupture of the membranes(20). In addition to these measures, the results of a meta-analysis
of four trials suggests that treatment of mothers expected to deliver before 36 weeks
gestation with glucocorticoids (eg. -methasone) reduces the risk of cerebral palsy. In the
Australasian Collaborative Trial of Magnesium Sulphate, magnesium sulfate treatment of
mothers at risk for preterm birth before 30 weeks gestation reduced the risk of substantial
gross motor dysfunction, and in a multicenter randomized trial in France a trend towards a
reduction in cerebral white matter damage was observed. More information about the
possible beneficial of antenatal magnesium sulfate is expected soon from the National
Institutes of Health Maternal Fetal Medicine Network trial (Benefits of Antenatal
Magnesium Sulfate).
In preterm infants, caffeine is the only therapy that has been shown in a multicenter trial to
decrease the risk of cerebral palsy. In this trial, extremely low birth weight infants were
randomized to caffeine or placebo in the first days of life. While the results might apply only
to a small proportion of preterm infants, it is this subgroup that is at highest risk of cerebral
palsy. Postnatal steroids, given to premature infants to decrease lung inflammation and
decrease the risk of bronchopulmonary dysplasia, increase the risk of cerebral palsy. Thus
limiting the use of this treatment can be expected to reduce the risk of cerebral palsy. The
goal of recently completed trial by the National Institutes of Health Neonatal Research
Network was to study the effect of aggressive phototherapy for hyperbilirubinemia on
neurodevelopmental outcome. The results of this trial may be relevant to the prevention of
cerebral palsy in extremely low birth weight infants.
Summary
Cerebral palsy is relatively common cause of persistent motor impairment and is associated
with a variety of developmental disabilities. In developing countries, approximately one half
of cases occur in prematurely born infants, and in this group the prevalence of cerebral palsy
in developed countries appears to be decreasing over the past decade. In full term infants,
the prevalence has been remarkably stable despite the advent of continuous fetal heart rate
monitoring. The care of children with cerebral palsy requires a multidisciplinary,
OShea
Page 8
Reference List
(1). Paneth N, Hong T, Korzeniewski S. The descriptive epidemiology of cerebral palsy. Clinics in
Perinatology 2006;33(2):251. + [PubMed: 16765723]
(2). Rosenbaum P. A report: the definition and classification of cerebral palsy April 2006 (vol 49, pg 8,
2007). Developmental Medicine and Child Neurology 2007;49(6):480.
(3). Rosenbaum P, Walter SD, Hanna SE, Palisano R, Russell DJ, Raina P, et al. Prognosis for gross
motor function in cerebral palsy. JAMA 2002;288(11):13571363. [PubMed: 12234229]
(4). Surveillance of Cerebral Palsy in Europe (SCPE). Surveillance of cerebral palsy in Europe: a
collaboration of cerebral palsy surveys and registers. Dev Med Child Neurol 2000;42:816824.
[PubMed: 11132255]
(5). Shankaran S, Laptook AR, Ehrenkranz RA, Tyson JE, McDonald SA, Donovan EF, et al. Wholebody hypothermia for neonates with hypoxic-ischemic encephalopathy. New England Journal of
Medicine 2005;353(15):15741584. [PubMed: 16221780]
(6). Kuban KCK, OShea M, Allred E, Leviton A, Gilmore H, DuPlessis A, et al. Video and CD-ROM
as a training tool for performing neurologic examinations of 1-year-old children in a multicenter
epidemiologic study. Journal of Child Neurology 2005;20(10):829831. [PubMed: 16417880]
(7). OShea TM. Cerebral palsy in very preterm infants: New epidemiological insights. Mental
Retardation and Developmental Disabilities Research Reviews 2002;8(3):135145. [PubMed:
12216057]
(8). Cooley WC. Providing a primary care medical home for children and youth with cerebral.
Pediatrics 2004;114(4):11061113. [PubMed: 15466117]
(9). Dickinson HO, Parkinson KN, Ravens-Sieberer U, Schirripa G, Thyen U, Arnaud C, et al. Selfreported quality of life of 8-12-year-old children with cerebral palsy: a cross-sectional European
study. Lancet 2007;369(9580):21712178. [PubMed: 17604799]
(10). Leviton A, Kuban K, Paneth N. Intraventricular haemorrhage grading scheme: time to abandon?
Acta Paediatrica 2007;96(9):12541256. [PubMed: 17590196]
(11). Hintz SR, OShea M. Neuroimaging and neurodevelopmental outcomes in preterm infants.
Semin Perinatol 2008;32(1):1119. [PubMed: 18249235]
(12). Wu YW, Shah SJ, Newman TB, Najjar DV, Croen LA. Cerebral palsy in a term population: Risk
factors and neuroimaging findings. Annals of Neurology 2006;60:S115.
(13). Ashwal S, Russman BS, Blasco PA, Miller G, Sandler A, Shevell M, et al. Practice parameter:
Diagnostic assessment of the child with cerebral palsy - Report of the Quality Standards
Subcommittee of the American Academy of Neurology and the Practice Committee of the Child
Neurology Society. Neurology 2004;62(6):851863. [PubMed: 15037681]
(14). Nelson KB. The epidemiology of cerebral palsy interm infants. Mental Retardation and
Developmental Disabilities Research Reviews 2002;8(3):146150. [PubMed: 12216058]
(15). Hunt RW, Inder TE. Perinatal and neonatal ischaemic stroke: A review. Thrombosis Research
2006;118(1):3948. [PubMed: 16709474]
(16). Hankins GDV, MacLennan AH, Speer ME, Strunk A, Nelson K. Obstetric litigation is
asphyxiating our maternity services. Obstetrics and Gynecology 2006;107(6):13821385.
[PubMed: 16738167]
(17). Brennan TA, Sox CM, Burstin HR. Relation between negligent adverse events and the outcomes
of medical-malpractice litigation. New England Journal of Medicine 1996;335(26):19631967.
[PubMed: 8960477]
Clin Obstet Gynecol. Author manuscript; available in PMC 2011 March 9.
OShea
Page 9
(18). Di Tommaso M, Tranquilli AL. A checklist to identify the origin of cerebral palsy. Journal of
Maternal-Fetal and Neonatal Medicine 2006;15:281286. [PubMed: 15280116]
(19). MacLennan A. A template for defining a causal relation between acute intrapartum events and
cerebral palsy: international consensus statement. British Medical Journal 1999;319(7216):1054
1059. [PubMed: 10521205]
(20). Iams JD, Romero R, Culhane JF, Goldenberg RL. Preterm birth 2 - Primary, secondary, and
tertiary interventions to reduce the morbidity and mortality of preterm birth. Lancet
2008;371(9607):164175. [PubMed: 18191687]
OShea
Page 10
Figure 1.
OShea
Page 11
Figure 2.
OShea
Page 12
Figure 3.
Alogorithm for evaluation of the child with cerebral palsy. Reprinted with permission from
Ashwal S, Russman BS, Blasco PA, Miller G, Sandler A, Shevell M, Stevenson R; Quality
Standards Subcommittee of the American Academy of Neurology; Practice Committee of
the Child Neurology Society. Practice parameter: diagnostic assessment of the child with
cerebral palsy: report of the Quality Standards Subcommittee of the American Academy of
Neurology and the Practice Committee of the Child Neurology Society. Neurology. 2004
Mar 23;62(6):851-63
OShea
Page 13
Table 1
Therapy
# studies (#
patients
studied)
# randomized
trials (#
patients
randomized)
Conclusions
3 (52)
3 (52)
Not provided
4 (183)
2 (44)
2 (44)
3 (90)
3 (90)
21 (473)
9 (238)
(1)
(2)
(3)
(4)
(5)
OShea
Page 14
Table 2
Therapy
# studies (#
patients
studied)
# randomized
trials (# patients
randomized)
Conclusions
11 (46)
1 (20)
3 (94)
2 (49)
6 (449)
2 (137)
(1)
(2)
(3)
Ade-Hall RA, Moore AP. Cochrane Collaboration . 2000. McDonagh MS, Morgan D, Carson S, Russman BS. Dev Med Child Neurol 2007;
49:942-947.